Substance / Medication

Terconazole

Overview

Active Ingredient
terconazole
RxNorm CUI
37806

Indications

Candida Terconazole vaginal cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream 0.4% is effective only for vulvovaginitis caused by the genus, the diagnosis should be confirmed by KOH smears and/or cultures.

Labeler: E. Fougera & Co. a division of Fougera Pharmaceuticals, LLCUpdated: 2026-01-28T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Patients known to be hypersensitive to terconazole or to any of the components of the cream.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Lecithin Microemulsion Lipogels Versus Conventional Gels for Skin Targeting of Terconazole: In Vitro, Ex Vivo, and In Vivo Investigation.
Talaat Sara M, Elnaggar Yosra S R, Abdalla Ossama Y · AAPS PharmSciTech · 2019
PMID: 30969396Observational
Chills, fatigue, chest distress, and an abnormal increase in WBC, neutrophil, CRP, and PCT induced by terconazole: A case report.
Li Xuemei, Yang Xiaohong, Wang Kejing et al. · Int J Clin Pharmacol Ther · 2021
PMID: 33860751Case Report
Cyclodextrin Stabilized Freeze-Dried Silica/Chitosan Nanoparticles for Improved Terconazole Ocular Bioavailability.
Zaghloul Nada, El Hoffy Nada M, Mahmoud Azza A et al. · Pharmaceutics · 2022
PMID: 35335847OtherFull text (PMC)
Cationic Polymeric Nanoparticles for Improved Ocular Delivery and Antimycotic Activity of Terconazole.
Mohsen Amira Mohamed · J Pharm Sci · 2022
PMID: 34547306Preclinical
Development of the stability-indicating method, structural elucidation of new photodegradation products from terconazole by LC-MS TOF, and in vitro toxicity.
da Silva José Wellithom Viturino, Ribeiro José Izak, de Souza Larissa Xavier et al. · J Pharm Biomed Anal · 2022
PMID: 35561435Preclinical
PLGA-modified Syloid-based microparticles for the ocular delivery of terconazole: in-vitro and in-vivo investigations.
Zaghloul Nada, Mahmoud Azza A, Elkasabgy Nermeen A et al. · Drug Deliv · 2022
PMID: 35838555PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Terconazole (substance)
SNOMED CT
387140007
UMLS CUI
C0076115
RxNorm CUI
37806
Labeler
E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.